Trial reportBiological psychiatry. Cognitive neuroscience and neuroimaging2025
Computationally Informed Insights Into Anhedonia and Treatment by Kappa Opioid Receptor Antagonism.
Trial report in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Probing biomarkers and clinical utility of reward learning across species using the Probabilistic Reward Task: 20 years of findings.Nature. Mental health · 2026Article
- Neural and behavioral signatures of policy compression in cognitive control.Cerebral cortex (New York, N.Y. : 1991) · 2025Article
- Time and memory costs jointly determine a speed-accuracy trade-off and set-size effects.Journal of experimental psychology. General · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAnhedonia, the loss of pleasure, is prevalent and impairing. Parsing its computational basis promises to explain its transdiagnostic character. One manifestation of anhedonia, reward insensitivity, may be linked to limited memory. Furthermore, the need to economize on limited memory engenders a perseverative bias toward frequently chosen actions. Anhedonia may also be linked with deviations from optimal perseveration for a given memory capacity, a pattern that causes inefficiency because it results in less reward for the same memory cost.
methodsTo test these hypotheses, we applied a theory of optimal decision making under memory constraints that decomposes behavior into a memory component and an efficiency component. We applied this theory to behavior on the Probabilistic Reward Task, a reward learning paradigm that has been validated in anhedonia, and performed secondary analysis of a randomized controlled trial testing kappa opioid receptor (KOR) antagonism for anhedonia (n = 24 KOR; n = 31 placebo), as well as analyses of 3 other datasets (n = 100, 66, 24, respectively). We fit a resource-bounded reinforcement learning model to behavior.
resultsAcross clinical and nonclinical populations, anhedonia was associated with deficits in efficiency but not memory. The reinforcement learning models demonstrated that deficits in efficiency arise from the inability to perseverate optimally. KOR antagonism, which likely elevates tonic dopamine, increases both memory and efficiency, and the model demonstrated that this arises from increased reward sensitivity and perseveration.
conclusionsTherefore, KOR antagonism has distinct cognitive effects, only one related to anhedonia. These findings have potential implications for the applications of KOR antagonists.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.